Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.
暂无分享,去创建一个
Ji-Ying Song | Jos H Beijnen | H. Rosing | J. Beijnen | A. V. van Herwaarden | O. van Tellingen | A. Schinkel | M. A. van der Valk | E. Wagenaar | Ji-Ying Song | J. V. D. van der Hoorn | J. Smit | C. M. M. van der Kruijssen | Hilde Rosing | Olaf van Tellingen | Alfred H Schinkel | Els Wagenaar | José W A van der Hoorn | Johan W Smit | Robert A B van Waterschoot | R. A. V. van Waterschoot | Antonius E van Herwaarden | Cornelia M M van der Kruijssen | Martin A van der Valk
[1] R. Fontana,et al. Molecular and physical mechanisms of first-pass extraction. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[2] T. Baillie,et al. Is the role of the small intestine in first-pass metabolism overemphasized? , 1999, Pharmacological reviews.
[3] T. Kamataki,et al. P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate. , 1987, The Journal of biological chemistry.
[4] P. Watkins,et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. , 2003, Journal of applied physiology.
[5] L. Benet,et al. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.
[6] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.
[7] L. Maltais,et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. , 2004, Pharmacogenetics.
[8] G. Wilkinson,et al. Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.
[9] G. de Sousa,et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. , 1996, Cancer research.
[10] H. Koepsell,et al. Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene , 2001, Molecular and Cellular Biology.
[11] F. Guengerich,et al. Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.
[12] E. Schuetz,et al. Corticosterone 6 beta-hydroxylase in A6 epithelia: a steroid-inducible cytochrome P-450. , 1990, The American journal of physiology.
[13] J. Schellens,et al. MIDAZOLAM AND CYCLOSPORIN A METABOLISM IN TRANSGENIC MICE WITH LIVER-SPECIFIC EXPRESSION OF HUMAN CYP3A4 , 2005, Drug Metabolism and Disposition.
[14] L B Sheiner,et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] E. Schuetz,et al. Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.
[16] J. Schellens,et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. , 2002, Cancer research.
[17] J. Brockmöller,et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[18] Edward M. Rubin,et al. Megabase deletions of gene deserts result in viable mice , 2004, Nature.
[19] N. Fineberg,et al. Association Between the CYP3A5 Genotype and Blood Pressure , 2005, Hypertension.
[20] H. Yamazaki,et al. Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes , 2000, Xenobiotica; the fate of foreign compounds in biological systems.
[21] H. Hense,et al. No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy. , 2006, Clinical science.
[22] J. Schellens,et al. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. , 2005, Biomedical chromatography : BMC.
[23] P. Watkins,et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] K. Lindros,et al. Hormonal regulation of the zonated expression of cytochrome P-450 3A in rat liver. , 1995, The Biochemical journal.
[25] J. Verweij,et al. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review , 2005, British Journal of Cancer.
[26] J. Spence,et al. Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.
[27] K. Korzekwa,et al. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. , 1998, Pharmacogenetics.
[28] A. Galetin,et al. Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism , 2006, Journal of Pharmacology and Experimental Therapeutics.